Bavarian Nordic Announces First Patient Treated in a Phase 2 Study Evaluating its Immunotherapy Candidate CV-301 in Bladder Cancer

April 28, 2014 Bavarian Nordic A/S announced today the first patient has now been treated in a randomized, prospective Phase 2 study of its active immunotherapy candidate CV-301 in bladder cancer. In the study, sponsored by the National Cancer Institute, 54 patients with high grade non-muscle invasive bladder cancer whose cancer has progressed after initial BCG (Bacillus Calmette-Guerin) treatment will …